Normally, a Cost-Effectiveness Analysis (part of Health Technology Assessment (HTA)) regarding a new technology/treatment is used to apply for reimbursement. Gradually we see that HTA not only is involved in policy- and coverage decisions, but also in an earlier stage in the translational research process to anticipate on technological and environmental developments (early HTA). A cost-effectiveness analysis is often performed after a clinical trial, early HTA can be performed in late stage of R&D, during phase I/II or feasibility trials. In these stages, advanced modeling techniques are used. The overall purpose is to steer towards cost-effective solutions and early patient access.
Our facility can support in all types of HTA related research alongside the translational research process, such as: cost-effectiveness analyses, budget impact analyses, exploring barriers and facilitators for implementation, multicriteria decision analysis for prioritization of research, and scenario drafting. Question can come from clinicians (AVL) as well as researchers (NKI).
We offer also support in the preparation, submission and trial for the very promising technologies/treatments: “veelbelovende zorg”
- Cost-effectiveness Analysis (trial based and model-based)
- Budget Impact Analysis
- Discrete Event Simulation
- Discrete Choice Experiment (patient preferences)
- Multi Criteria Decision Analysis (MCDA) for prioritization
- Exploring barriers and facilitators (regarding a new technology/treatment/application)
- QoL questionnaires (including preferences based instruments)